Management Team
Cutanea has experienced leadership that brings extensive expertise in business, dermatology, drug and device development and product commercialization to our company. To execute our programs, we supplement our experienced team with contractors and consultants who have significant clinical and regulatory expertise in dermatological product development. The members of this team share a commitment to developing novel therapies for the treatment of diverse skin conditions in areas of unsatisfied aesthetic and medical need.
Robert J. Bitterman – President, Chief Executive Officer, and Director – Robert J. Bitterman joined Cutanea in September 2005 as its President, Chief Executive Officer, and a director. From September 2004 until April 2005, he served as President and Chief Executive Officer of Isolagen, Inc., a publicly traded international bioscience company possessing a proprietary technology for application of human autologous fibroblasts. From 1994 until 2004, Mr. Bitterman served as President and General Manager of Aventis Global Dermatology (f/k/a Dermik Laboratories), the global dermatological strategic business unit of Aventis S.A., where he worked on numerous commercial product launches in the U.S. and other strategic international markets. Prior to assuming senior operational leadership positions, Mr. Bitterman held various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Also during his tenure with Aventis, Mr. Bitterman was responsible for constructing and managing an operating joint venture in the People’s Republic of China. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He is a member of the Woman’s Dermatology Society, the Derm Foundation, and the Philadelphia Business Leaders Network. He also holds a Doctor of Human Letters (Honoris Causa) from the New York College of Podiatric Medicine.
Kimberley Forbes-McKean, Ph.D. – Executive Vice President and Chief Scientific Officer – Kimberley Forbes-McKean, Ph.D. joined Cutanea in October 2005 as its Executive Vice President and Chief Scientific Officer. Dr. Forbes-McKean has broad technical and managerial experience gained from over 20 years in a variety of multi-cultural environments in various areas in the pharmaceutical and biotechnology industries. From September 2004 until July 2005, she served as Senior Vice President and Chief Technical Science Officer of Isolagen, Inc., a biotechnology company working to develop their proprietary technology on human autologous fibroblasts. Dr. Forbes-McKean has held various research management positions at Baxter Healthcare Corporation, and Sanofi-Aventis Pharmaceuticals (f/k/a/ Rhone-Poulenc Rorer and Aventis). During her 14-year tenure with Sanofi-Aventis, Dr. Forbes-McKean assumed positions of increasing responsibility. From 2000 to 2004, she was responsible for all aspects of global dermatological product development, culminating with her role as Vice President of Dermatological Product Development & Commercialization of Aventis Global Dermatology (f/k/a Dermik Laboratories). During Dr. Forbes-McKean’s tenure, Aventis gained approval to launch six new drug products and a novel Class 3 medical device in the U.S., E.U., and other parts of the world. Dr. Forbes-McKean holds a B.S. in Chemistry from Union College in Schenectady, NY and an M.S. and Ph.D. in Analytical Chemistry from the University of Massachusetts at Amherst, MA. She supplemented her academic graduate experience with an internship at Merck, Sharp and Dohme Research Laboratories, completed research projects for other pharmaceutical companies during her thesis work, and was recognized with a Merck Research Fellowship Award.
James McMonagle, Jr., CPA — James M. McMonagle, Jr. joined Cutanea in August 2010 as its interim Chief Financial Officer. He is currently a Senior Financial Consultant with Rife & Associates, a management consulting firm that provides part-time CFO services to growing businesses and management consulting services to businesses of all sizes. Mr. McMonagle is currently part-time CFO to several small growth businesses. From October 2005 to May 2008, he served as Corporate Controller of Lannett Company, Inc., a publicly traded manufacturer of generic pharmaceuticals. At Lannett, he was responsible for SEC financial reporting and Sarbanes-Oxley compliance, in addition to strategic development and financial systems. From May 2008 until February 2010, Mr. McMonagle served as Chief Financial & Accounting Officer of GPX Enterprises, a private equity enterprise with investments in real estate and technology companies. His previous experience includes four years at Deloitte & Touche. Mr. McMonagle holds a B.S. in Accounting from Villanova University.
